Abstract
Aims: To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI)in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD. Further, todetermine temporal trends, and risk factors for non-use.
Methods and Results: Using Danish nationwide registers, we performed a cross-sectional study investigating the utilization of betablockers, aspirin and statins after hospitalisation for first-time MI among patients with and without COPD from 1995to 2015. Risk factors for non-use were examined in multivariable logistic regression models. During 21 years of study, 140,278 patients were included, hereof 13,496 (9.6%) with COPD. Patients with COPD were less likely to use beta-blockers (53.2% vs. 76.2%, P < 0.001), aspirin (73.9% vs. 78.8%, P < 0.001), and statins (53.5% vs. 61.9%, P < 0.001). Medication usage increased during the study period but inmultivariable analyses, COPD remained a significant predictor for non-use: OR [95% CI] for non-use of betablockers 1.86 [1.76-1.97]; aspirin 1.24 [1.16-1.32]; statins 1.50 [1.41-1.59]. Analyses stratified by ST-segmentelevation myocardial infarction (STEMI) and non-STEMI showed similar undertreatment of COPD patients. Risk factors for non-use of beta-blockers in COPD included increasing age, female sex, andincreasing severity of COPD (frequent exacerbations, use of multiple inhaled medications, low lung function). Similar findings were demonstrated for aspirin and statins.
Conclusion: Beta-blockers, and to a lesser extent aspirin and statins, were systematically underutilized by patients with COPD following hospitalisation for MI despite an overall increase in the utilization over time. Increasing severity of COPDwas a risk factor for non-use of the medications.
| Original language | English |
|---|---|
| Journal | European heart journal. Quality of care & clinical outcomes |
| ISSN | 2058-1742 |
| DOIs | |
| Publication status | E-pub ahead of print - 4. Jan 2019 |
Fingerprint
Keywords
- Chronic obstructive pulmonary disease (COPD)
- Treatment
- Multimorbidity
Cite this
}
Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease : a nationwide analysis from 1995 to 2015 in Denmark. / Rasmussen, Daniel Bech; Bodtger, Uffe; Lamberts, Morten; Nicolaisen, Sia Kromann; Sessa, Maurizio; Capuano, Annalisa; Torp-Pedersen, Christian; Gislason, Gunnar; Lange, Peter; Jensen, Magnus Thorsten.
In: European heart journal. Quality of care & clinical outcomes, 04.01.2019.Research output: Contribution to journal › Journal article › Research › peer-review
TY - JOUR
T1 - Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease
T2 - a nationwide analysis from 1995 to 2015 in Denmark
AU - Rasmussen, Daniel Bech
AU - Bodtger, Uffe
AU - Lamberts, Morten
AU - Nicolaisen, Sia Kromann
AU - Sessa, Maurizio
AU - Capuano, Annalisa
AU - Torp-Pedersen, Christian
AU - Gislason, Gunnar
AU - Lange, Peter
AU - Jensen, Magnus Thorsten
N1 - E-pub.
PY - 2019/1/4
Y1 - 2019/1/4
N2 - Aims: To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI)in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD. Further, todetermine temporal trends, and risk factors for non-use.Methods and Results: Using Danish nationwide registers, we performed a cross-sectional study investigating the utilization of betablockers, aspirin and statins after hospitalisation for first-time MI among patients with and without COPD from 1995to 2015. Risk factors for non-use were examined in multivariable logistic regression models. During 21 years of study, 140,278 patients were included, hereof 13,496 (9.6%) with COPD. Patients with COPD were less likely to use beta-blockers (53.2% vs. 76.2%, P < 0.001), aspirin (73.9% vs. 78.8%, P < 0.001), and statins (53.5% vs. 61.9%, P < 0.001). Medication usage increased during the study period but inmultivariable analyses, COPD remained a significant predictor for non-use: OR [95% CI] for non-use of betablockers 1.86 [1.76-1.97]; aspirin 1.24 [1.16-1.32]; statins 1.50 [1.41-1.59]. Analyses stratified by ST-segmentelevation myocardial infarction (STEMI) and non-STEMI showed similar undertreatment of COPD patients. Risk factors for non-use of beta-blockers in COPD included increasing age, female sex, andincreasing severity of COPD (frequent exacerbations, use of multiple inhaled medications, low lung function). Similar findings were demonstrated for aspirin and statins.Conclusion: Beta-blockers, and to a lesser extent aspirin and statins, were systematically underutilized by patients with COPD following hospitalisation for MI despite an overall increase in the utilization over time. Increasing severity of COPDwas a risk factor for non-use of the medications.
AB - Aims: To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI)in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD. Further, todetermine temporal trends, and risk factors for non-use.Methods and Results: Using Danish nationwide registers, we performed a cross-sectional study investigating the utilization of betablockers, aspirin and statins after hospitalisation for first-time MI among patients with and without COPD from 1995to 2015. Risk factors for non-use were examined in multivariable logistic regression models. During 21 years of study, 140,278 patients were included, hereof 13,496 (9.6%) with COPD. Patients with COPD were less likely to use beta-blockers (53.2% vs. 76.2%, P < 0.001), aspirin (73.9% vs. 78.8%, P < 0.001), and statins (53.5% vs. 61.9%, P < 0.001). Medication usage increased during the study period but inmultivariable analyses, COPD remained a significant predictor for non-use: OR [95% CI] for non-use of betablockers 1.86 [1.76-1.97]; aspirin 1.24 [1.16-1.32]; statins 1.50 [1.41-1.59]. Analyses stratified by ST-segmentelevation myocardial infarction (STEMI) and non-STEMI showed similar undertreatment of COPD patients. Risk factors for non-use of beta-blockers in COPD included increasing age, female sex, andincreasing severity of COPD (frequent exacerbations, use of multiple inhaled medications, low lung function). Similar findings were demonstrated for aspirin and statins.Conclusion: Beta-blockers, and to a lesser extent aspirin and statins, were systematically underutilized by patients with COPD following hospitalisation for MI despite an overall increase in the utilization over time. Increasing severity of COPDwas a risk factor for non-use of the medications.
KW - Chronic obstructive pulmonary disease (COPD)
KW - Treatment
KW - Multimorbidity
U2 - 10.1093/ehjqcco/qcy063
DO - 10.1093/ehjqcco/qcy063
M3 - Journal article
JO - European heart journal. Quality of care & clinical outcomes
JF - European heart journal. Quality of care & clinical outcomes
SN - 2058-1742
ER -